Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive pre-clinical data for Resverlogix drug
The company now intends to focus on an Investigational New Drug (IND) application to support clinical development. “As part of our preparations for human clinical trials, we have
The company now intends to focus on an Investigational New Drug (IND) application to support clinical development. “As part of our preparations for human clinical trials, we have
The warning letter addresses three general areas: monitoring, securing investigator compliance with the protocol and reporting, the company said. Medical systems developer BSD added that the concerns outlined
NeuroVax has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax appears to work by enhancing levels of FOXP3+ regulatory T-cells (Treg cells)
The patent was licensed by Princeton to Chiron Corp, who subsequently licensed it to Bayer HealthCare. Princeton had conceded priority to Enzo over the patent. Another interference involving
The injunction had been in effect since May 2006, following the filing of Dusa's complaint alleging that River's Edge's product infringes Dusa's patent. Nicomide is one of the
SL-401 has demonstrated single agent anti-tumor activity in a phase I dose escalation study. Thirty adult patients with relapsed, refractory, or poor risk acute myeloid leukemia (AML) were
The drug has been approved to reduce the risk of nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, and chest
The Medicines and Healthcare products Regulatory Agency (MHRA) has said the advert claims that Zyvox has superior cure rates compared to products containing the active ingredient vancomycin. Pfizer
The global agreement covers all territories except the US. Named patient distribution refers to the distribution or sale of a product to a specific healthcare professional for the
In March 2004, Aeras and Crucell entered into a collaborative agreement for the development of a PER.C6 and AdVac-based TB vaccine. The vaccine entered the phase I clinical